H. Sullivan

发表

Ionic Channels of Excitable Membranes, 2nd Ed.

H. Sullivan, 1992, Neurology.

Electrogenic Ion Pumps (Distinguished Lecture Series of the Society of General Physiologists, Vol. 5)

H. Sullivan, 1992, Neurology.

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Annelot M. Dekker, A. Destée, S. Bates, 2017, The Lancet Neurology.

Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis.

F. Lublin, J. Wolinsky, P. Narayana, 2001, Archives of neurology.

Linomide in relapsing and secondary progressive MS

F. Lublin, J. Wolinsky, H. Sullivan, 2000, Neurology.

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

H. Sullivan, A. Coles, D. Margolin, 2011, Blood.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

H. Sullivan, K. Selmaj, A. Coles, 2012, Neurology.

Linomide in relapsing and secondary progressive MS

J. Wolinsky, P. Narayana, H. Sullivan, 2000, Neurology.

Fatal tonsilar herniation in pseudotumor cerebri

H. Sullivan, 1991, Neurology.

A single‐arm, open‐label study of alemtuzumab in treatment‐refractory patients with multiple sclerosis

H. Sullivan, L. Mayer, E. Fox, 2012, European journal of neurology.

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Alexander Parajeles Vindas, P. Kowey, D. Arnold, 2016, Neurology. Clinical practice.

Lateral deviation of the eyes on forced lid closure in patients with cerebral lesions.

R. Leigh, J. Weissman, H. Sullivan, 1991, Archives of neurology.

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Annelot M. Dekker, A. Destée, S. Bates, 2017, The Lancet Neurology.